J Immunol Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19

[tetano]

J Immunol


. 2020 Jun 3;ji2000513.
doi: 10.4049/jimmunol.2000513. Online ahead of print.
Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19


Jeremy K Y Yap ¹ , Miyu Moriyama ² , Akiko Iwasaki ^{3 4 5}



Affiliations

• PMID: 32493814
• DOI: 10.4049/jimmunol.2000513

Abstract

The inflammatory response to severe acute respiratory syndrome-related coronavirus 2 infection has a direct impact on the clinical outcomes of coronavirus disease 2019 patients. Of the many innate immune pathways that are engaged by severe acute respiratory syndrome-related coronavirus 2, we highlight the importance of the inflammasome pathway. We discuss available pharmaceutical agents that target a critical component of inflammasome activation, signaling leading to cellular pyroptosis, and the downstream cytokines as a promising target for the treatment of severe coronavirus disease 2019-associated diseases.